Anaemia and transfusion in critical illness
Th e traditional goal for packed red blood cell (PRBC) transfusion was traditionally 10 g/dL, and revised down to <7 g/dL [2] with the exception of acute coronary syndromes or acute resuscitation. Unfortunately, there have been no large, prospective trials of PRBC transfusion in patients specifi cally with neurologic disease.
Anaemia in the neurologically critically ill
Anaemia is associated with worse outcomes in nontraumatic subarachnoid hemorrhage (ruptured brain aneurysm) [3] . Preventing brain hypoxia might be impor tant to reduce the incidence and severity of cerebral infarction from vasospasm, and PRBC transfusion in that setting leads to improved markers of brain tissue function on positron emission tomography [4] . In patients with traumatic brain injury, brain oxygen monitors may show low brain oxygen tension that responds to PRBC trans fusion [5] ; the BOOST2 study is planned to assess if brain oxygen tension-guided therapy improves outcomes. A sub-study of the Transfusion Requirements in the Critical Care trial found no apparent eff ect of goal haemoglobin concentration on functional outcomes after neurotrauma [6] .
Why would anaemia after intracerebral haemorrhage matter? Intracerebral haemorrhage does not lead to vasospasm, but cerebral infarction can be found on magnetic resonance imaging scans [7] and this may impact outcomes. Th ere is probably not hypoxia around the clot [8] , but there may be altered metabolism for a period of several days [9] .
Remarkably few patients received a PRBC transfusion in the cohort, usually for surgery. Th e nadir haemoglobin for patients with poor outcome (11.5 g/dL) was above the usual trigger for transfusion, so these data are of limited usefulness in determining when a PRBC transfusion should be given.
What one should think of anaemia in the neurologically critically ill is likely to depend on one's preconceived notions. If you are convinced that anaemia in the Neuro-ICU is linked to worse neuronal function, cerebral ischemia and poor outcome, you will probably (successfully) justify keeping your trigger for PRBC
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transfusion at <10 g/dL. If you are convinced these observational data simply show sicker patients have worse outcomes despite the statistical correction for older age and larger haemorrhage size, then you will probably (successfully) justify keeping your trigger for PRBC transfusion at <7 g/dL. If you have a specifi c physiologic trigger (reduced brain oxygen tension, increased oxygen extraction fraction on positron emission tomography, and so on), few will argue with you. As Benjamin Franklin said, 'So convenient a thing it is to be a reasonable creature, since it enables one to fi nd or make a reason for everything one has a mind to do. '
Conclusion
Anaemia is generally associated with worse outcomes in neurologically critically ill patients. Whether the outcome can be improved by more frequent use of PRBC transfusion remains unclear.
Abbreviations PRBC = packed red blood cell.
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